Business
Notice of Interim Results
Notice of Interim Results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6349E Sareum Holdings PLC 13 February 2018 \n\n\n\n\n\n(AIM: SAR)\n\n\n13 February 2018\n\n\n\n\n \nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\nNotice of Interim Results\nSareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, announces that it expects to release its interim results for the six months to 31 December 2017 in the first two weeks of March.\n-Ends-\n \nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n\n020 7282 9571\n\n\n\n\nNotes for editors: \nSareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nIts most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.\nSareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.\nThe Company's drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.\nSareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk \n- Ends -\n \n\nThis information is provided by RNSThe company news service fr...